Many enzymes implicated in oncology and inflammation are difficult to target with traditional active-site inhibitors, limiting therapeutic options. These enzymes often possess exosites, allosteric binding pockets distinct from the active site, which can modulate enzyme activity but are challenging to identify and drug.

Exo Therapeutics leverages its ExoSight™ platform to discover and develop small molecule inhibitors that target exosites on enzymes relevant to oncology and inflammation. By focusing on these exosites, Exo Therapeutics aims to achieve more precise and potent modulation of enzyme activity compared to conventional active-site targeting. This approach expands the druggable target space, potentially unlocking new therapeutic interventions for diseases where traditional methods have proven insufficient. The ExoSight™ platform provides a comprehensive approach to identify and characterize exosites, enabling the design of selective inhibitors.

ExoSight™ platform for exosite identification and characterization

Development of small molecule inhibitors targeting enzyme exosites

Focus on oncology and inflammation pathways

Precise and potent modulation of enzyme activity

Potential to drug previously intractable targets

The primary target audience includes patients with cancer and inflammatory diseases, as well as pharmaceutical companies seeking novel drug targets and therapeutic strategies.